BASKING RIDGE, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verizon Frontline today announced Dejero as the latest partner to earn "Verizon Frontline Verified" status. Dejero manufactures GateWay network aggregation devices that deliver high-quality live video and real-time data over IP. Dejero joins Panorama Antennas in meeting the high standards required to become "Verizon Frontline Verified." "This is yet another milestone for Dejero that will positively impact our emergency response communities," said Jehan ...

What you need to know: The Verizon Frontline Crisis Response Team supported first responders participating in the exerciseAdvanced communication technologies helped ensure seamless coordination across jurisdictions and organizationsVerizon provided multiple mission-critical communications solutions SOUTHPORT, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Verizon Frontline Crisis Response Team recently completed a deployment in support of first responders participating in a Nuclear Hostile Action Exercise in B ...

Core Viewpoint - HOOKIPA Pharma Inc. is set to present updated Phase 2 data for eseba-vec (HB200) in combination with pembrolizumab for treating first-line recurrent/metastatic HPV16-positive head and neck cancer at the upcoming SITC 2024 conference [1][3]. Group 1: Presentation Details - The late-breaking poster presentation will be conducted by Dr. Alan Ho from Memorial Sloan Cancer Center on November 9, 2024, from 9:00 AM to 8:00 PM CDT [2][3]. - The abstract title for the presentation is "Eseba-vec (HB-200) plus pembrolizumab as first-line treatment of recurrent/metastatic HPV16-positive head and neck cancer: updated results in PD-L1 CPS ≥20 patients" [3]. Group 2: Product Information - Eseba-vec (HB-200) is an investigational immunotherapeutic agent targeting HPV16 positive cancers, specifically for patients with HPV16+ recurrent/metastatic oropharyngeal squamous cell carcinoma (R/M OPSCC) with a PD-L1 CPS of 20 or higher [4]. - The drug has received Fast Track Designation from the U.S. FDA and PRIME designation from the European Medicines Agency for its potential use in first-line treatment of HPV16+ OPSCC [4]. Group 3: Company Overview - HOOKIPA Pharma Inc. focuses on developing next-generation immunotherapeutics using its proprietary arenavirus platform, aiming to induce robust CD8+ T cells and antibodies to combat cancers and serious infectious diseases [5]. - The company's pipeline includes therapies targeting HPV16+ cancers, KRAS mutated cancers, and partnerships with Gilead for developing treatments for hepatitis B virus and HIV-1 [5].

Wayne, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Frontline Education, a leading provider of administration software purpose-built for educators in K-12, today announced a new partnership with Equifax®, a global data, analytics, and technology company, to offer The Work Number®, a robust income and employment verification service, to its Enterprise Resource Planning (ERP) clients in Texas and California. The Work Number® provides ERP clients with more seamless access to income and employment verification servic ...

--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.79 [95% CI, 0.42-1.50])-- -- 38% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.62 [95% CI, 0.23-1.70]) -- -- Strength of neoantigen specific T cell respo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the six months ended June 30, 2024 Commission File Number: 001-16601 FRONTLINE PLC (Translation of registrant's name into English) John Kennedy, 8 Iris Building, 7th Floor, Flat/Office 740B, 3106, Limassol (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual ...

CHICAGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Verizon Frontline Crisis Response Team recently completed a deployment in support of federal, state and local public safety agencies during the Democratic National Convention. The Verizon Frontline Crisis Response Team’s preparations for this high-profile event started more than 18 months ago and required close collaboration with dozens of federal, state and county agencies to help ensure first responders had the mission-critical communications capabilities th ...

MILWAUKEE, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Verizon Frontline Crisis Response Team recently completed a deployment in support of the Milwaukee Police Department, one of the lead agencies responsible for coordination of all public safety activity during the Republican National Convention. The Verizon Frontline Crisis Response Team’s preparations for this event started more than 18 months ago and required close collaboration with local, state and federal public safety agencies to identify the unique nee ...

Antony VelikagathuNote: I covered Frontline plc (NYSE:FRO) in January 2024. I prized the company’s large fleet, strong balance sheet, and reasonable valuation. At that time, tanker market fundamentals were supportive. The crude oil tanker order book was below 5%, and the number of ships older than 20 years was rising. On the other hand, tonne-mile demand was resilient due to the Red Sea crisis and stable oil demand. In conclusion, I gave FRO a Buy rating. In May, FRO’s share price reached $28.6/share, o ...

Financial Data and Key Metrics Changes - Frontline reported a profit of $187.6 million or $0.84 per share for Q2 2024, with an adjusted profit of $138.2 million or $0.62 per share, comparable to Q1 2024 [5][6] - The TCE earnings decreased by $12.4 million due to the disposal of two VLCCs and two Suezmax tankers, offset by reduced operating expenses and increased interest income of $12.6 million [5][6] - Strong liquidity of $567 million in cash and cash equivalents was reported, with no newbuilding commitments and no significant debt maturities until 2027 [6][8] Business Line Data and Key Metrics Changes - TCE numbers for Q2 2024 were $49,600 per day for VLCCs, $45,600 for Suezmaxes, and $53,100 for LR2/Aframax fleets [4] - For Q3, 79% of VLCC days are booked at $47,400, 85% of Suezmax days at $49,900, and 65% of LR2/Aframax days at $50,100 [4] Market Data and Key Metrics Changes - 23% of the global fleet is involved in sanction trade, with 17% of the VLCC fleet under scrutiny [12][13] - Global oil demand is on track, with oil in transit rising and world inventories at historical lows [14][20] - The order book for VLCCs remains low, while Suezmax is medium low and LR2 is high, with no new orders in the last 1.5 months [21] Company Strategy and Development Direction - The company is focusing on optimizing capital structure through refinancing and divesting older vessels, having completed the sale of four vessels [7][8] - A two-tier market is developing, with a compliant market and a growing dark or grey fleet, which could create volatility [16][17] - The company anticipates a strong earnings capacity moving into the second half of the year, driven by seasonal demand increases [22] Management's Comments on Operating Environment and Future Outlook - Management noted geopolitical risks in the Middle East and the impact of sanctions on trade, but expressed optimism for the upcoming winter season [3][12] - The company expects oil consumption to increase by 1.5 million barrels from August to December, indicating a seasonal uptick in demand [19] - Concerns were raised about China's oil imports and the potential impact on global demand, but management remains hopeful for demand growth from other regions [30][31] Other Important Information - The average cash breakeven rates for the next 12 months are estimated at approximately $29,600 per day for VLCCs, $22,300 for Suezmaxes, and $21,200 for LR2s [9][10] - The company has a strong balance sheet with sensible leverage on its modern fleet, positioning it well for future opportunities [22] Q&A Session Summary Question: Are there any more big refinancings expected before 2027? - Management indicated that there are no material refinancings expected before 2027, with the divestiture of older vessels also completed [24][25] Question: What is driving the VLCC performance in Q3? - Management attributed the performance to the successful integration of a new fleet from Euronav and strategic booking practices [34][35] Question: How will the recent pullback in Libyan exports affect crude trade dynamics? - Management noted that while it may impact Aframaxes, VLCCs would likely see minimal effect as other sources could compensate for lost volumes [38][39] Question: What is the outlook for Iranian crude exports under increased scrutiny? - Management expressed skepticism about vessels returning to the compliant market, suggesting that the aging compliant fleet would continue to supply the grey market [42][43] Question: How does the company plan to utilize excess cash if the market improves? - Management stated that excess cash would be returned to investors unless a compelling investment opportunity arises [56]